a Department of Clinical Medicine , University of Bergen , Bergen , Norway.
b Department of Neurology , Haukeland University Hospital , Bergen , Norway.
Expert Opin Biol Ther. 2019 Mar;19(3):261-271. doi: 10.1080/14712598.2019.1568407. Epub 2019 Jan 23.
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. The latest development of B-cell depletion by anti-CD20 monoclonal antibodies has been a large step forward in the treatment of this devastating disease.
In this manuscript, we review mechanisms of action, efficacy, safety, and tolerance of anti-CD20 therapies for MS, including rituximab, ocrelizumab, and ofatumumab.
B-cell depletion efficiently suppresses acute inflammatory disease activity in relapsing-remitting MS (RRMS), and may slowdown progression in primary progressive MS (PPMS). The treatment is generally well tolerated, with manageable adverse events related to infusion reactions and infections. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, is the first therapy to be approved for the treatment of both RRMS and PPMS.
多发性硬化症（MS）是一种中枢神经系统的慢性炎症性疾病。抗 CD20 单克隆抗体对 B 细胞的耗竭是治疗这种毁灭性疾病的一大进步。
在本文中，我们回顾了抗 CD20 疗法治疗多发性硬化症的作用机制、疗效、安全性和耐受性，包括利妥昔单抗、奥瑞珠单抗和奥法妥木单抗。
B 细胞耗竭可有效抑制复发缓解型多发性硬化症（RRMS）的急性炎症性疾病活动，并可能减缓原发性进展型多发性硬化症（PPMS）的进展。该治疗通常具有良好的耐受性，与输注反应和感染相关的不良事件可管理。奥瑞珠单抗，一种人源化抗 CD20 单克隆抗体，是第一种被批准用于治疗 RRMS 和 PPMS 的药物。
